Charlie Kim

Partner
Full contact info

"Authentic Big Law" – Can we practice law at the very highest levels, while also in a personal, caring and team-focused way that rejects discrimination and self-promotion at the cost of others, and truly reflects the ideals we hold onto so dearly outside of work? We here at Team Cooley answer that question with a resounding "yes!"

Passions

Food

K-Dramas

College Football

Experience

Uber Technologies $8.1 Billion IPO

May 11, 2019

Cooley advised Uber on its $8.1 billion initial public offering of 207,000,000 shares of common stock. Uber, whose securities now trade on the NYSE under the symbol “UBER,” is a mobility platform revolutionizing the personal ridesharing, meal delivery and logistics industries. Partners Dave Peinsipp, Siana Lowrey, Drew Williamson, Charlie Kim and Kristin VanderPas led the Cooley team.

Related contacts

David Peinsipp
Partner, San Francisco
Siana Lowrey
Partner, San Francisco
Drew Williamson
Partner, San Francisco
Charlie Kim
Partner, San Diego
Kristin VanderPas
Partner, San Francisco
Arielle H. Friehling
Associate, San Francisco
Sam Meiklejohn
Associate, London

Related Practices & Industries

Sweetgreen – $418.6 Million IPO

December 6, 2021

Cooley advised restaurant chain sweetgreen on its $418.6 million initial public offering of 14,950,000 shares of Class A common stock, which now trade on the New York Stock Exchange under the symbol SG. Partners Nick Hobson, David Peinsipp, Siana Lowrey and Charlie Kim led the Cooley team advising sweetgreen.

Read more

Related contacts

Nick Hobson
Partner in Charge, Los Angeles – Santa Monica, Los Angeles Santa Monica
David Peinsipp
Partner, San Francisco
Siana Lowrey
Partner, San Francisco
Charlie Kim
Partner, San Diego
Julia Boesch
Partner, San Francisco
Mark Cikowski
Associate, Los Angeles Santa Monica
Marjorie Roesser
Associate, San Francisco
Eric Steiner
Paralegal Specialist, San Francisco
Amy Saldamando
Paralegal Specialist, Los Angeles Santa Monica
Kim Merritt
Paralegal Specialist, San Francisco
Barbara Mirza
Partner, Los Angeles Santa Monica
Austin Holt
Partner, Los Angeles Santa Monica
David Navetta
Partner, Colorado
Christian Lee
Associate, San Francisco
Maricel Mojares-Moore
Special Counsel, San Francisco
Matt Kong
Associate, San Francisco
Ross Eberly
Partner, Los Angeles Santa Monica
Eileen Leman
Associate, Los Angeles Downtown
Karen Tsai
Special Counsel, Washington, DC
Mark Windfeld-Hansen
Senior Counsel, Palo Alto
Stephanie Gentile
Partner, New York
John Paul Oleksiuk
Partner, New York
Colette Ghazarian
Associate, Los Angeles Downtown
Sharon Connaughton
Special Counsel, Washington, DC
Patrick Gibbs
Partner, Palo Alto
Francis Wheeler
Partner, Colorado
Michael Suyat
Senior Paralegal, San Francisco

Related Practices & Industries

10X Genomics – $449 Million IPO

September 12, 2019

Cooley advised underwriters on 10X Genomics’ $448.5 million initial public offering of 11,500,000 shares of Class A common stock, including full exercise of the underwriters’ option to purchase additional shares. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch acted as joint book-running managers. Cowen acted as lead manager. 10X Genomics’ securities now trade on the Nasdaq Global Select Market under the symbol “TXG.” Partners Charlie Kim, Dave Peinsipp and Kristin VanderPas led the Cooley team.

Related contacts

Charlie Kim
Partner, San Diego
David Peinsipp
Partner, San Francisco
Kristin VanderPas
Partner, San Francisco
Denny Won
Partner, San Francisco

Related Practices & Industries

ACELYRIN Announces Pricing of Upsized Initial Public Offering

May 15, 2023

Cooley advised Acelyrin, INC., a late-stage biopharmaceutical company, in its $621 million initial public offering, the second-largest biotechnology IPO and largest clinical-stage biotechnology IPO ever.

Read more

Related contacts

Chadwick Mills
Partner, San Francisco
Charlie Kim
Partner, San Diego
Anitha Anne
Associate, San Francisco
Barbara Mirza
Partner, Los Angeles Santa Monica
Xander Lee
Partner, Los Angeles Santa Monica
Joshua Mates
Partner, San Francisco
Phil Mitchell
Partner, New York
Brad Goldberg
Partner, New York
Peter Adams
Partner, San Diego
Lauren Creel
Partner, Palo Alto
Koji Fukumura
Partner, San Diego
Patrick Gibbs
Partner, Palo Alto
David Peinsipp
Partner, San Francisco
Barbara Borden
Partner, San Diego
David Navetta
Partner, Colorado
Patrick Van Eecke
Partner, Brussels
Shannon Eagan
Partner in Charge – Palo Alto, Palo Alto
Darren DeStefano
Partner, Reston
Francis Wheeler
Partner, Colorado
Thomas Welk
Senior Counsel, San Diego
Natasha Leskovsek
Of Counsel, Washington, DC
Brett White
Of Counsel, Palo Alto
Dani Nazemian
Special Counsel, San Diego
Jennifer Shanley
Special Counsel, New York
Jacquelyn Burke
Special Counsel, Boston
Karen Tsai
Special Counsel, Washington, DC
Miriam Petrillo
Partner, Chicago
Andrew Nelms
Associate, San Francisco
David D. Kim
Associate, San Francisco
Lawrence Traylor
Associate, Los Angeles Santa Monica
Dionne A. Thomas
Associate, San Diego
Nathaniel Hearn Jr.
Associate, New York
Valerie Sapozhnikova
Associate, Los Angeles Downtown
Eileen Leman
Associate, Los Angeles Downtown
Kelly McCormick
Associate, San Francisco
Mor Agam
Associate, New York
Allison Kutner
Associate, New York
Madison (JJ) Meng
Associate, San Francisco
Rebecca Siegel
Associate, San Francisco
Rachel F. Katz
Associate, New York
Mari Dugas
Associate, Washington, DC
Loriane Sangaré-Vayssac
Associate, Brussels
Megan Drill
Associate, San Diego
Amanda Pacheco
Associate, Palo Alto
Kristin R. Marshall
Associate, Washington, DC
John T. Stellini
Associate, Palo Alto
Luke X. Blackett
Associate, San Francisco

Related Practices & Industries

Structure Therapeutics – $185.3 Million IPO

February 9, 2023

San Francisco – February 9, 2023 Cooley advised Structure Therapeutics, a clinical-stage global biopharmaceutical company, on its $185.3 million initial public offering, including the full exercise of the underwriters’ option to purchase additional American depositary shares. Lawyers Charlie Kim, Patrick Loofbourrow, Andrew Harline and Su Lian Lu led the Cooley team.

The offering marks the first sizable US life sciences IPO this year. Structure Therapeutics will use the proceeds to develop new oral therapies for the treatment of various diseases, including those impacting the metabolic, cardiovascular and pulmonary systems. Its lead product candidate targets Type 2 diabetes and obesity.

Structure Therapeutics aims to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages structure-based drug discovery and computational chemistry expertise, enabling it to build a pipeline of product candidates. The company currently focuses on G-protein-coupled receptors as a therapeutic target class.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has nearly 1,400 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.

Related contacts

Charlie Kim
Partner, San Diego
Patrick Loofbourrow
Partner, Singapore
Andrew Harline
Partner in Charge – Singapore, Singapore
Su Lian Lu
Special Counsel, Los Angeles Santa Monica
Xander Lee
Partner, Los Angeles Santa Monica
Jie Zhang
Partner, Hong Kong
Phil Mitchell
Partner, New York
Aaron Pomeroy
Partner, Colorado
Carlos Ramirez
Partner, San Diego
Ryan Blair
Partner, San Diego
Joshua Mates
Partner, San Francisco
Mark Ballantyne
Partner, Reston
Nicola Squire
Partner, London
Francis Wheeler
Partner, Colorado
Will Cai
Partner, Hong Kong
Thomas Welk
Senior Counsel, San Diego
Natasha Leskovsek
Of Counsel, Washington, DC
Dani Nazemian
Special Counsel, San Diego
Randy Sabett
Special Counsel, Washington, DC
Bin Wang
Special Counsel, Palo Alto
Rebecca Ross
Special Counsel, Washington, DC
Lisa Yuan
Special Counsel, Beijing
Jennifer Shanley
Special Counsel, New York
Christine Turner
Associate, Colorado
Vince Flynn
Associate, San Diego
Ivy Wang
Associate, Shanghai
Rick Jantz
Associate, Los Angeles Santa Monica
Yuan Dai
Associate, Shanghai
Cara Buchicchio
Associate, New York
Megan Drill
Associate, San Diego
Daniel Gillon
Associate, San Diego
Dionne A. Thomas
Associate, San Diego
Cristina Ferruolo
Associate, San Diego
Brian Lau
International Legal Project Manager, Hong Kong
Jessica Wade
Paralegal Specialist, San Diego
Kate Walther
Paralegal Specialist, San Diego
Lunga Su
Associate, Shanghai
Christine S. Kim
Associate, San Diego
Andy Zachrich
Associate, San Diego

Related Practices & Industries

View more

Charlie Kim skillfully navigating your capital markets transactions - priceless. Charlie's depth and breadth of knowledge/experience was crucial in the successful execution of our IPO and multiple follow-on offerings which tallied to over $1.2 billion. Internally, we nicknamed Charlie the 'Ironman of Capital Markets'. He and his team were a pleasure to partner with from the pre-planning phase all the way through the end of the process.

Tom Walker, former CFO of Tableau Software

Rankings & accolades

Chambers USA: Band 1 for Capital Markets: Debt & Equity – California (2021 – 2023)

Chambers USA: Band 1 for Capital Markets: Debt & Equity: Western United States – Nationwide (2020 – 2023)

The Legal 500 US: Leading Lawyer in Capital Markets: Equity Offerings (2023) 

Daily Journal: Top 100 Lawyer across all specialties in California and recipient of the California Lawyer Attorneys of the Year Award

The Daily Transcript: San Diego Top Attorney

Law360: MVP of the Year – Capital Markets

Thomson Reuters: Super Lawyer – Southern California and San Diego

 

Memberships & affiliations

American Bar Association

Council of Korean Americans

New York State Bar Association

San Diego County Bar Association

Representative Issuers

Charlie has represented companies/investment banks on capital market transactions involving issuers across industries, such as: AbCellera, Accelerate, ACELYRIN, Acutus, Advaxis, Aerohive, Agenus, Akari, Akcea, Akero, Allogene, Alteryx, Ambrx, Amylin, Anadys, AnaptysBio, Angion, Annexon, Anthera, Apogee, Applied Molecular Transport, Arcadia, Arcus, Arcutis, Ardea, Arena, Aridis, Ascendis, ASLAN, Athira, Audentes, Avidity, Ballast Point Brewing & Spirits, Biomea, Cadence, Castlight, Cerus, Cidara, Clorox, Corcept, Crinetics, Cue Health, Cyan, Cytori, Day One, Dermira, Design, DICE, Doximity, Dynavax, eBay, EHang, Eidos, Elevation Oncology, Entropic, Erasca, Exagen, Evofem, Fangdd, FIGS, FireEye, Five Prime, Gemphire, Genomatica, Global Blood, Gossamer, Gracell, Graphite Bio, Gritstone, Guardant Health, Halozyme, Health Catalyst, Healthcare Royalty, HealthEquity, Horizon, IGM, Ignyta, Immune Design, IMV, Inhibrx, Inovio, Insys, Invitae, Ionis, Janux, Jazz Pharmaceuticals, Kamada, Kinnate, Kite Pharma, Kronos, Landry's, LifeLock, Limelight, Livongo, Longboard, Lyell, MannKind, Medallia, MethylGene, Metropark, MindBody, Minerva, Mirati, NantHealth, NantKwest, Nektar, Neon, Neumora, Neurocrine, ObsEva, Olink, Ooma, Optimer, ORIC, Otonomy, Pernix, Phathom, Poseida, PRA Holdings, PROCEPT, Progressive Gaming, ProNAi, ProQR, Proto Labs, Qualtrics, Quidel, Radiant Systems, Rani, Raptor, RayzeBio, Reata, Receptos, Regulus, ReSearch Pharmaceutical Services, Sana, Sangamo, Santarus, Savara, Seattle Genetics, Senomyx, Sequenom, ShockWave, Sierra, Silverback, Singular Genomics, Somaxon, Strongbridge, Structure, Surface Oncology, Sutro, Syndax, Tableau Software, Tabula Rasa, Taiwan Liposome Company, Tangoe, Tarsus, Third Harmonic, TRACON, Treace, Tricida, Trius, TriVascular, Uber Technologies, Vaxcyte, Ventyx Biosciences, Verenium, Verona, Vical, ViewRay, Vir, Vital Therapies, Vor, Xencor, Xenon, XenoPort, Zealand Pharma, Zentalis, Zogenix, Zscaler, Zymeworks, 4D Molecular Therapeutics,10x Genomics and 89bio.